One of the most established ingredients in the blood glucose control sector is chromium via its effects on insulin, with the picolinate form the most prevalent (structure shown above). A 2006 review by the FDA was not convinced by the science however, concluding that the “relationship between chromium picolinate intake and insulin resistance is highly uncertain”.
Eight years later, and a review in the Journal of Clinical Pharmacy and Therapeutics (2014, Vol. 39, pp. 292–306) came to a different conclusion. Thai scientists concluded: “The available evidence suggests favourable effects of chromium supplementation on glycaemic control in patients with diabetes. Chromium monosupplement may additionally improve triglycerides and HDL-C levels.
“Chromium supplementation at usual doses does not increase the risk of adverse events compared with placebo.”
Pharmachem offers a combination of chromium picolinate (Chromax) and L-arabinose, derived from the corn plant, which acts as a sucrase ‘blocker’, which reduces the digestion of sugar.
The company has science to support the activity of the ingredient, with pilot and clinical trials already completed.
Correction: This entry has been corrected to remove statements relating to chromium dinicocysteinate (Zychrome from InterHealth) outperforming established chromium picolinate supplements. These statements were incorrect: The NAD ruled in favor of Nutrition 21, manufacturers of the Chromax-branded chromium picolinate, regarding similar unsubstantiated claims and statements made about chromium dinicocysteinate. We apologize for this mistake.